SOLICITATION NOTICE
A -- Medication Discovery Using Rat Models of Relapse
- Notice Date
- 3/13/2024 6:28:33 AM
- Notice Type
- Solicitation
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- 75N95024R00011
- Response Due
- 4/1/2024 12:00:00 PM
- Archive Date
- 04/16/2024
- Point of Contact
- Llakim Dubroff, Phone: 3014436677, Tracy Cain, Phone: 3014436677
- E-Mail Address
-
llakim.dubroff@nih.gov, tracy.cain@nih.gov
(llakim.dubroff@nih.gov, tracy.cain@nih.gov)
- Description
- The National Institute on Drug Abuse (NIDA) intends to solicit proposals�from qualified organizations (NAICS Code 541715) having in-house�capability to develop methodologies and to perform in vivo rodent�behavioral pharmacology for other drug dependence disorders, using drug�self-administration reinstatement models. The object of this contract is to determine the in vivo efficacy of novel�compounds in animal models of relapse using cocaine, nicotine,�methamphetamine, or opioids. This includes the following tests in animals�trained to self-administer cocaine (for example): (1) the ability of test�compound to block footshock or other stress-induced reinstatement of�responding after a period of experimental extinction; (2) the ability of a test�compound to block priming-induced reinstatement of responding after a�period of extinction; and (3) the ability of a test compound to block the�effects of a conditioned cue (previously paired with the training drug) to�reinstate responding for the training drug (cocaine, nicotine,�methamphetamine, or an opioid) after a period of extinction. An integral part of this work is to develop methods and to design and�implement protocols for the evaluation of test compounds. A number of�laboratories have used some of the methodologies described in the�literature. While recognizing the need for methods development, NIDA�anticipates that by Option Period 1, if Options are exercised, the majority of�the Contractor�s efforts will be devoted to test compound evaluations. The�Contractor shall identify and acquire standard compounds that merit the�aforementioned types of evaluation. In addition, if NIDA exercises specific�contract options, this contract shall support follow-up rodent pharmacology studies of compounds identified as promising potential�drug-dependence treatment agents including through the use of drug selfadministration�studies. The details of these latter studies cannot be�specified before contract award; they will depend upon specific successes�in NIDA�s medication discovery efforts and scientific advances in the�general field of drug abuse research. Written reports documenting the�study findings are the anticipated end products of this contract. Mandatory Criteria: Due to the nature of the compounds which will be evaluated under this�contract, it is mandatory that offerors possess prior to award US�Department of Justice Drug Enforcement Administration (DEA) Research�Registration for Schedules II to V in order to handle substances under the�Controlled Substances Act of 1970. In addition, the successful offeror must�either possess or demonstrate the ability to obtain prior to award DEA�registration for Schedule I controlled substances. The offeror must demonstrate its understanding and compliance with the�NIH Guide for Care and Use of Laboratory Animals. The Offeror shall�submit evidence that its proposal was reviewed and approved by the�Institution�s Animal Care and Use Committee (IACUC). The Assurance�number shall be provided with the proposal. Notice: We anticipate the award of one cost-reimbursement, level of effort contract�for a base period of one year with four one-year options to extend�performance. The contract will include additional quantity options. RFP No. 75N95024R00011 will be available electronically on or about 45�days from the date of this posting. You can access the RFP through the�sam.gov (URL: http://sam.gov) or through the NIDA website: (URL:http://www.drugabuse.gov/funding/funding-opportunities/nida-requestscontract-proposals-rfps ). All information required for the submission of a�proposal will be contained in or accessible through the RFP package. Responses to the RFP will be due 45 days from the release date. NIDA�anticipates a July 2024 award date. NIDA will consider proposals submitted�by any responsible offeror. Based upon market research, the Government is not using the policies�contained in Part 12, Acquisition of Commercial Items, in its solicitation for�the described supplies or services. However, interested persons may�identify to the Contracting Officer their interest and capability to satisfy the�Government�s requirement with a commercial item within 15 days of this�notice. This advertisement does not commit the Government to award a contract. For more details please see the attached RFP.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/76382f54dc4d46be8c7a4153198e47bf/view)
- Place of Performance
- Address: Rockville, MD, USA
- Country: USA
- Country: USA
- Record
- SN06995090-F 20240315/240313230042 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |